(11Z,14Z)-2-(trimethylazaniumyl)icosa-11,14-dienoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (11Z,14Z)-2-(trimethylazaniumyl)icosa-11,14-dienoate
• 化学式: C23H43NO2
• 分子量: 365.6
• InChiKey: KLFBYCJWBSSJQH-UTJQPWESSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.3
• 重原子数：
  26
• 可旋转键数：
  16
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  40.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• PHARMACEUTICAL COMPOSITIONS
  申请人：RHYTHM METABOLIC, INC.

  公开号：US20160022764A1

  公开（公告）日：2016-01-28

  The present invention relates to an ionic complex comprising a cationic polypeptide and an anionic excipient selected from: a PEG-carboxylic acid; a fatty acid having 10 or more carbon atoms; an anionic phospholipid; and a combination thereof. The invention also relates to a pharmaceutical composition comprising the ionic complex of the invention and a pharmaceutically acceptable carrier. The cationic polypeptide of the ionic complex has pharmacological activity and the complex can provide a more desirable pharmacokinetic profile for the cationic polypeptide of the complex as compared to the cationic polypeptide alone following administration. As such, the invention also relates to the use of the ionic complex and pharmaceutical composition comprising same to treat a subject suffering from a disease or disorder that is responsive to the cationic polypeptide of the ionic complex.

  本发明涉及一种离子复合物，包括阳离子多肽和阴离子辅料，所述阴离子辅料选自：PEG-羧酸；具有10个或更多碳原子的脂肪酸；阴离子磷脂；以及其组合物。该发明还涉及一种药物组合物，包括本发明的离子复合物和药学上可接受的载体。离子复合物的阳离子多肽具有药理活性，并且与仅使用阳离子多肽相比，复合物可以提供更理想的药代动力学特性。因此，本发明还涉及使用离子复合物和包括其的药物组合物来治疗对离子复合物的阳离子多肽有反应的疾病或障碍的患者。
• ANTI-TNF-ALPHA ANTIBODY PREPARATION, PREPARATION METHOD THEREFOR AND USE THEREOF
  申请人：Bio-Thera Solutions, Ltd.

  公开号：EP4108258A1

  公开（公告）日：2022-12-28

  The present invention relates to the field of pharmacy, and provides an anti-TNF-a antibody formulation, and a preparation method and use thereof, wherein the formulation comprises an anti-TNF-a antibody and a pharmaceutically acceptable carrier, the anti-TNF-a antibody comprises a heavy chain with an amino acid sequence set forth in SEQ ID NO: 1 and a light chain with an amino acid sequence set forth in SEQ ID NO: 2, and the pharmaceutically acceptable carrier comprises a stabilizer, a surfactant and a buffer. The antibody formulation of the present invention has high stability and does not support microorganism growth.

  本发明涉及药学领域，提供了一种抗TNF-a抗体制剂及其制备方法和用途，其中制剂包括抗TNF-a抗体和药学上可接受的载体，抗TNF-a抗体包括SEQ ID NO: 1所示氨基酸序列的重链和SEQ ID NO: 2所示氨基酸序列的轻链，药学上可接受的载体包括稳定剂、表面活性剂和缓冲剂。本发明的抗体制剂稳定性高，不支持微生物生长。
• Methods of preparing ophthalmic formulations and uses of same
  申请人：Cognoptix, Inc.

  公开号：US10350309B2

  公开（公告）日：2019-07-16

  The present invention relates to a process for preparing an ointment comprising subjecting a mixture of a fluorescent molecular rotor compound, mineral oil, and grinding media to ball milling agitation and combining this mixture with a hydrophobic vehicle for an ointment. The invention also relates to an ophthalmic formulation comprising a pharmaceutically acceptable carrier and a compound of the following structural Formula (I), or a pharmaceutically acceptable salt thereof: Values and preferred values of the variables in structural Formula (I) are described herein.

  本发明涉及一种制备软膏的工艺，包括将荧光分子转子化合物、矿物油和研磨介质的混合物进行球磨搅拌，并将该混合物与软膏的疏水性载体结合。本发明还涉及一种眼科制剂，该制剂包含一种药学上可接受的载体和一种结构式（I）如下的化合物或其药学上可接受的盐： 结构式（I）中各变量的值和优选值在此描述。
• Pharmaceutical compositions
  申请人：RHYTHM PHARMACEUTICALS, INC.

  公开号：US11129869B2

  公开（公告）日：2021-09-28

  The present invention relates to an ionic complex comprising a cationic polypeptide and an anionic excipient selected from: a PEG-carboxylic acid; a fatty acid having 10 or more carbon atoms; an anionic phospholipid; and a combination thereof. The invention also relates to a pharmaceutical composition comprising the ionic complex of the invention and a pharmaceutically acceptable carrier. The cationic polypeptide of the ionic complex has pharmacological activity and the complex can provide a more desirable pharmacokinetic profile for the cationic polypeptide of the complex as compared to the cationic polypeptide alone following administration. As such, the invention also relates to the use of the ionic complex and pharmaceutical composition comprising same to treat a subject suffering from a disease or disorder that is responsive to the cationic polypeptide of the ionic complex.

  本发明涉及一种离子复合物，其包括阳离子多肽和从以下物质中选择的阴离子赋形剂:聚乙二醇-羧酸；含10个或更多碳原子的脂肪酸；阴离子磷脂；以及上述物质的组合。本发明还涉及一种包含本发明的离子复合物和药学上可接受载体的药物组合物。所述离子复合物中的阳离子多肽具有 pharmacological 活性，且与所述阳离子多肽单独给药相比，该复合物能够为所述多肽提供更具优势的 pharmacokinetic 特性。因此，本发明还涉及使用所述离子复合物及其药物组合物治疗患有对所述离子复合物中的阳离子多肽有响应的疾病或障碍的受试者。
• METHODS OF PREPARING OPHTHALMIC FORMULATIONS AND USES OF SAME
  申请人：Cognoptix, Inc.

  公开号：EP3062821A1

  公开（公告）日：2016-09-07